Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study

References

• Abdellatif AG, Preat V, Taper HS, Roberfroid M. (1991). The modulation of rat liver carcinogenesis by perfluorooctanoic acid, a peroxisome proliferator. Toxicol Appl Pharmacol, 111, 530–7
   PubMedGoogle Scholar
• Abdellatif AG, Preat V, Vamecq J, et al. (1990). Peroxisome proliferation and modulation of rat liver carcinogenesis by 2,4-dichlorophenoxyacetic acid, 2,4,5-trichlorophenoxyacetic acid, perfluorooctanoic acid and nafenopindichlorophenoxyacetic acid, 2,4,5-trichlorophenoxyacetic acid, perfluorooctanoic acid and nafenopin. Carcinogenesis, 11, 1899–1902
   PubMed Web of Science ®Google Scholar
• Akiyama TE, Nicol CJ, Fievet C, et al. (2001). Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines. J Biol Chem, 276, 39088–93
   PubMed Web of Science ®Google Scholar
• Alsarra IA, Brockmann WG, Cunningham ML, Badr MZ. (2006). Hepatocellular proliferation in response to agonists of peroxisome proliferator-activated receptor alpha: a role for Kupffer cells? J Carcinog, 5, 26
   PubMedGoogle Scholar
• Amacher DE, Beck R, Schomaker SJ, Kenny CV. (1997). Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat. Toxicol Appl Pharmacol, 142, 143--50
   Google Scholar
• Andersen ME, Preston RJ, Maier A, et al. (in press). Dose-response approaches for nuclear receptor-mediated modes of action for liver carcinogenicity: results of a workshop. Crit Rev Toxicol
   Google Scholar
• Anderson SP, Dunn C, Laughter A, et al. (2004a). Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver. Mol Pharmacol, 66, 1440–52
   PubMed Web of Science ®Google Scholar
• Anderson SP, Howroyd P, Liu J, et al. (2004b). The transcriptional response to a peroxisome proliferator-activated receptor alpha agonist includes increased expression of proteome maintenance genes. J Biol Chem, 279, 52390–8
   PubMed Web of Science ®Google Scholar
• Anderson SP, Dunn CS, Cattley RC, Corton JC. (2001). Hepatocellular proliferation in response to a peroxisome proliferator does not require TNFalpha signaling. Carcinogenesis, 22, 1843–51
   PubMedGoogle Scholar
• Anderson SP, Yoon L, Richard EB, et al. (2002). Delayed liver regeneration in peroxisome proliferator-activated receptor-alpha-null mice. Hepatology, 36, 544–54
   PubMed Web of Science ®Google Scholar
• Aoyama T, Peters J, Iritani N, et al. (1998). Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J Biol Chem, 273, 5678–84
   PubMed Web of Science ®Google Scholar
• Arsura M, Cavin LG. (2005). Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett, 229, 157–69
   PubMed Web of Science ®Google Scholar
• Ashby J, Brady A, Elcombe CR, et al. (1994). Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol, 13, S1–117
   PubMed Web of Science ®Google Scholar
• Austin EW, Okita JR, Okita RT, et al. (1995). Modification of lipoperoxidative effects of dichloroacetate and trichloroacetate is associated with peroxisome proliferation. Toxicology, 97, 59–69
   PubMed Web of Science ®Google Scholar
• Auwerx J, Schoonjans K, Fruchart JC, Staels B. (1996a). Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis, 124, S29–37
   PubMed Web of Science ®Google Scholar
• Auwerx J, Schoonjans K, Fruchart JC, Staels B. (1996b). Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. J Atheroscler Thromb, 3, 81–9
   PubMedGoogle Scholar
• Barber ED, Astill BD, Moran EJ, et al. (1987). Peroxisome induction studies on seven phthalate esters. Toxicol Ind Health, 3, 7–24
   PubMed Web of Science ®Google Scholar
• Barrass NC, Price RJ, Lake BG, Orton TC. (1993). Comparison of the acute and chronic mitogenic effects of the peroxisome proliferators methylclofenapate and clofibric acid in rat liver. Carcinogenesis, 14, 1451–6
   PubMed Web of Science ®Google Scholar
• Bayly AC, Roberts RA, Dive C. (1994). Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin. J Cell Biol, 125, 197–203
   PubMed Web of Science ®Google Scholar
• Becuwe P, Dauça M. (2005). Comparison of cytotoxicity induced by hypolipidemic drugs via reactive oxygen species in human and rodent liver cells. Int J Mol Med, 16, 483–92
   PubMedGoogle Scholar
• Bell AR, Savory R, Horley NJ, et al. (1998). Molecular basis of non-responsiveness to peroxisome proliferators: the guinea-pig PPARα is functional and mediates peroxisome proliferator-induced hypolipidaemia. Biochem J, 332, 689–93
   PubMedGoogle Scholar
• Bell DR, Plant NJ, Rider CG, et al. (1993). Species-specific induction of cytochrome P-450 4A RNAs: PCR cloning of partial guinea-pig, human and mouse CYP4A cDNAs. Biochem J, 294, 173–80
   PubMed Web of Science ®Google Scholar
• Bentley P, Calder I, Elcombe C, et al. (1993). Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol, 31, 857–907
   PubMed Web of Science ®Google Scholar
• Bichet N, Chard D, Fabre G, et al. (1990). Toxicological studies on a benzofuran derivative. III. Comparison of peroxisome proliferation in rat and human hepatocytes in primary culture. Toxicol Appl Pharmacol, 106, 509–17
   PubMedGoogle Scholar
• Biddie SC, Hager GL. (2009). Glucocorticoid receptor dynamics and gene regulation. Stress, 12, 193–205
   PubMed Web of Science ®Google Scholar
• Biddie SC, John S, Hager GL. (2010). Genome-wide mechanisms of nuclear receptor action. Trends Endocrinol Metab, 21, 3–9
   PubMedGoogle Scholar
• Biegel LB, Hurtt ME, Frame SR, et al. (2001). Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol Sci, 60, 44–55
   PubMed Web of Science ®Google Scholar
• Bility MT, Thompson JT, McKee RH, et al. (2004). Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. Toxicol Sci, 82, 170–82
   PubMed Web of Science ®Google Scholar
• Blumcke S, Schwartzkopff W, Lobeck H, et al. (1983). Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis, 46, 105–16
   PubMed Web of Science ®Google Scholar
• Bojes HK, Germolec DR, Simeonova P, et al. (1997). Antibodies to tumor necrosis factor alpha prevent increases in cell replication in liver due to the potent peroxisome proliferator WY14 643. Carcinogenesis, 18, 669–74
   PubMed Web of Science ®Google Scholar
• Boobis AR, Cohen SM, Dellarco V, et al. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol, 36, 781–92
   PubMed Web of Science ®Google Scholar
• Boobis AR, Datson GP, Preston RJ, Olin SS. (2009). Application of key events analysis to chemical carcinogens and noncarcinogens. Crit Rev Food Sci Nutr, 49, 690–707
   PubMed Web of Science ®Google Scholar
• Boobis AR, Doe JE, Heinrich-Hirsch B, et al. (2008). IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol, 38, 87–96
   PubMed Web of Science ®Google Scholar
• Bull RJ, Orner GA, Cheng RS, et al. (2002). Contribution of dichloroacetate and trichloroacetate to liver tumor induction in mice by trichloroethylene. Toxicol Appl Pharmacol, 182, 55–65
   PubMed Web of Science ®Google Scholar
• Bull RJ, Sanchez IM, Nelson MA, et al. (1990). Liver tumor induction in B6C3F1 mice by dichloroacetate and trichloroacetate. Toxicology, 63, 341–59
   PubMed Web of Science ®Google Scholar
• Burkhardt S, Mellert W, Reinacher M, Bahnenmann R. (2001). Zonal evaluation of proliferation and apoptosis in mice reveals new mechanistic data for PB, WY 14 643 and CH. Toxicologist, 60, 286
   Google Scholar
• Bursch W, Lauer B, Timmermann-Trosiener I, et al. (1984). Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis, 5, 453–8
   PubMed Web of Science ®Google Scholar
• Busser MT, Lutz WK. (1987). Stimulation of DNA synthesis in rat and mouse liver by various tumor promoters. Carcinogenesis, 8, 1433–7
   PubMedGoogle Scholar
• Cai Y, Appelkvist EL, DePierre JW. (1995). Hepatic oxidative stress and related defenses during treatment of mice with acetylsalicylic acid and other peroxisome proliferators. J Biochem Toxicol, 10, 87–94
   PubMedGoogle Scholar
• Caira F, Clémencet MC, Cherkaoui-Malki M, et al. (1998). Differential regulation by a peroxisome proliferator of the different multifunctional proteins in guinea pig: cDNA cloning of the guinea pig D-specific multifunctional protein 2. Biochem J, 330, 1361–8
   PubMedGoogle Scholar
• Calfee-Mason KG, Lee EY, Spear BT, Glauert HP. (2008). Role of the p50 subunit of NF-kappaB in vitamin E-induced changes in mice treated with the peroxisome proliferator, ciprofibrate. Food Chem Toxicol, 46, 2062–73
   PubMedGoogle Scholar
• Calfee-Mason KG, Spear BT, Glauert HP. (2004). Effects of vitamin E on the NF-kappaB pathway in rats treated with the peroxisome proliferator, ciprofibrate. Toxicol Appl Pharmacol, 199, 1–9
   PubMedGoogle Scholar
• Cariello NF, Romach EH, Colton HM, et al. (2005). Gene expression profiling of the PPARα agonist ciprofibrate in the cynomolgus monkey liver. Toxicol Sci, 88, 250–64
   PubMed Web of Science ®Google Scholar
• Cattley RC, Conway JG, Popp JA. (1987). Association of persistent peroxisome proliferation and oxidative injury with hepatocarcinogenicity in female F-344 rats fed di(2-ethylhexyl)phthalate for 2 years. Cancer Lett, 38, 15–22
   PubMed Web of Science ®Google Scholar
• Cattley RC, DeLuca J, Elcombe C, et al. (1998). Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol, 27, 47–60
   Web of Science ®Google Scholar
• Cattley RC, Glover SE. (1993). Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: relationship to carcinogenesis and nuclear localization. Carcinogenesis, 14, 2495–9
   PubMed Web of Science ®Google Scholar
• Cattley RC, Marsman DS, Popp JA. (1991). Age-related susceptibility to the carcinogenic effect of the peroxisome proliferator WY14 643 in rat liver. Carcinogenesis, 12, 469–73
   PubMed Web of Science ®Google Scholar
• Cattley RC, Popp JA. (1989). Differences between the promoting activities of the peroxisome proliferator WY-14, 643 and phenobarbital in rat liver. Cancer Res, 49, 3246–51
   PubMed Web of Science ®Google Scholar
• Chan E, Tan CS, Deurenberg-Yap M, et al. (2006). The V227A polymorphism at the PPARΑ locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women. Atherosclerosis, 187, 309–15
   PubMedGoogle Scholar
• Chen H, Huang CY, Wilson MW, et al. (1994). Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cell proliferation and toxicity in Sprague Dawley rats. Carcinogenesis, 15, 2847–50
   PubMedGoogle Scholar
• Cheung C, Akiyama TE, Ward JM, et al. (2004). Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res, 64, 3849–54
   PubMed Web of Science ®Google Scholar
• Chinje E, Kentish P, Jarnot B, et al. (1994). Induction of the CYP4A subfamily by perfluorodecanoic acid: the rat and the guinea pig as susceptible and non-susceptible species. Toxicol Lett, 71, 69–75
   PubMed Web of Science ®Google Scholar
• Choudhury AI, Chahal S, Bell AR, et al. (2000). Species differences in peroxisome proliferation; mechanisms and relevance. Mutat Res, 448, 201–12
   PubMed Web of Science ®Google Scholar
• Choudhury AI, Sims HM, Horley NJ, et al. (2004). Molecular analysis of peroxisome proliferation in the hamster. Toxicol Appl Pharmacol, 197, 9–18
   PubMedGoogle Scholar
• Christensen JG, Gonzales AJ, Cattley RC, Goldsworthy TL. (1998). Regulation of apoptosis in mouse hepatocytes and alteration of apoptosis by nongenotoxic carcinogens. Cell Growth Differ, 9, 815–25
   PubMedGoogle Scholar
• Cohen SM, Klaunig J, Meek ME, et al. (2004). Evaluating the human relevance of chemically induced animal tumors. Toxicol Sci, 78, 181–6
   PubMed Web of Science ®Google Scholar
• Cohen SM, Meek ME, Klaunig JE, et al. (2003). The human relevance of information on carcinogenic modes of action: overview. Crit Rev Toxicol, 33, 581–9
   PubMed Web of Science ®Google Scholar
• Columbano A, Ledda-Columbano GM, Pibiri M, et al. (2001). Peroxisome proliferator-activated receptor-alpha mice show enhanced hepatocyte proliferation in response to the hepatomitogen 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene, a ligand of constitutive androstane receptor. Hepatology, 34, 262–6
   PubMedGoogle Scholar
• Committee of Principal Investigators. (1978). A cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J, 40, 1069–118
   PubMedGoogle Scholar
• Conway JG, Tomaszewski KE, Olson MJ, et al. (1989). Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and Wy-14 643. Carcinogenesis, 10, 513–9
   PubMed Web of Science ®Google Scholar
• Cornu-Chagnon MC, Dupont H, Edgar A. (1995). Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundam Appl Toxicol, 26, 63–74
   PubMedGoogle Scholar
• Corton JC. (2008). Evaluation of the role of peroxisome proliferator-activated receptor alpha (PPARα in mouse liver tumor induction by trichloroethylene and metabolites. Crit Rev Toxicol, 38, 857–75
   PubMed Web of Science ®Google Scholar
• Corton JC. (2010). Mode of action analysis and human relevance of liver tumors induced by PPARα activation. In: Hsu C-H, Stedeford T, eds. Cancer risk assessment: chemical carcinogenesis, hazard evaluation, and risk quantification. Hoboken (NJ): John Wiley & Sons, Inc, 438--81
   Google Scholar
• Corton JC, Anderson SP, Stauber A. (2000). Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol, 40, 491–518
   PubMed Web of Science ®Google Scholar
• Corton JC, Apte U, Anderson SP, et al. (2004). Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors. J Biol Chem, 279, 46204–12
   PubMed Web of Science ®Google Scholar
• Corton JC, Bocos C, Moreno ES, et al. (1996). Rat 17 beta-hydroxysteroid dehydrogenase type IV is a novel peroxisome proliferator-inducible gene. Mol Pharmacol, 50, 1157–66
   PubMed Web of Science ®Google Scholar
• Corton JC, Brown-Borg HM. (2005). Peroxisome proliferator-activated receptor gamma coactivator 1 in caloric restriction and other models of longevity. J Gerontol A Biol Sci Med Sci, 60, 1494–509
   PubMedGoogle Scholar
• Corton JC, Lapinskas PJ. (2005). Peroxisome proliferator-activated receptors: mediators of phthalate ester-induced effects in the male reproductive tract? Toxicol Sci, 83, 4–17
   PubMed Web of Science ®Google Scholar
• Costet P, Legendre C, More J, et al. (1998). Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem, 273, 29577–85
   PubMed Web of Science ®Google Scholar
• Cruciani V, Rast C, Durand MJ, et al. (1997). Comparative effects of clofibrate and methyl clofenapate on morphological transformation and intercellular communication of Syrian hamster embryo cells. Carcinogenesis, 18, 701–6
   PubMedGoogle Scholar
• Cunningham ML, Collins BJ, Hejtmancik MR, et al. (2010). Effects of the PPARα agonist and widely used antihyperlipidemic drug gemfibrozil on hepatic toxicity and lipid metabolism. PPAR Res, 2010, Article ID, 681963
   Google Scholar
• Currie RA, Bombail V, Oliver JD, et al. (2005). Gene ontology mapping as an unbiased method for identifying molecular pathways and processes affected by toxicant exposure: application to acute effects caused by the rodent non-genotoxic carcinogen diethylhexylphthalate. Toxicol Sci, 86, 453–69
   PubMed Web of Science ®Google Scholar
• Czaja MJ. (2007). Cell signaling in oxidative stress-induced liver injury. Semin Liver Dis, 27, 378–89
   PubMed Web of Science ®Google Scholar
• David RM, Moore MR, Cifone MA, et al. (1999). Chronic peroxisome proliferation and hepatomegaly associated with the hepatocellular tumorigenesis of di(2-ethylhexyl)phthalate and the effects of recovery. Toxicol Sci, 50, 195–205
   PubMed Web of Science ®Google Scholar
• David RM, Moore MR, Finney DC, Guest D. (2000a). Chronic toxicity of di(2-ethylhexyl)phthalate in mice. Toxicol Sci, 58, 377–85
   PubMed Web of Science ®Google Scholar
• David RM, Moore MR, Finney DC, Guest D. (2000b). Chronic toxicity of di(2-ethylhexyl)phthalate in rats. Toxicol Sci, 55, 433–43
   PubMed Web of Science ®Google Scholar
• de Duve C. (1996). The peroxisome in retrospect. Ann NY Acad Sci, 804, 1–10
   PubMedGoogle Scholar
• de la Iglesia FA, Lewis JE, Buchanan RA, et al. (1982). Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis, 43, 19–37
   PubMed Web of Science ®Google Scholar
• De Minicis S, Bataller R, Brenner DA. (2006). NADPH oxidase in the liver: defensive, offensive, or fibrogenic? Gastroenterology, 131, 272–5
   PubMed Web of Science ®Google Scholar
• DeAngelo AB, Daniel FB, McMillan L, et al. (1989). Species and strain sensitivity to the induction of peroxisome proliferation by chloroacetic acids. Toxicol Appl Pharmacol, 101, 285–98
   PubMed Web of Science ®Google Scholar
• DeAngelo AB, Daniel FB, Most BM, Olson GR. (1997). Failure of monochloroacetic acid and trichloroacetic acid administered in the drinking water to produce liver cancer in male F344/N rats. J Toxicol Environ Health, 52, 425–45
   PubMed Web of Science ®Google Scholar
• Dees C, Travis C. (1994). Trichloroacetate stimulation of liver DNA synthesis in male and female mice. Toxicol Lett, 70, 343–55
   PubMed Web of Science ®Google Scholar
• Delerive P, Gervois P, Fruchart JC, Staels B. (2000). Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem, 275, 36703–7
   PubMed Web of Science ®Google Scholar
• Dellarco VL, Baetcke K. (2005). A risk assessment perspective: application of mode of action and human relevance frameworks to the analysis of rodent tumor data. Toxicol Sci, 86, 1–3
   PubMed Web of Science ®Google Scholar
• DeLuca JG, Doebber TW, Kelly LJ, et al. (2000). Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARα-null mice. Mol Pharmacol, 58, 470–6
   PubMed Web of Science ®Google Scholar
• Desvergne B, Ijpenberg A, Devchand PR, Wahli W. (1998). The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signaling. J Steroid Biochem Mol Biol, 65, 65–74
   PubMedGoogle Scholar
• Desvergne B, Wahli W. (1999). Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev, 20, 649–88
   PubMed Web of Science ®Google Scholar
• Dostalek M, Hardy KD, Milne GL, et al. (2008). Development of oxidative stress by cytochrome P450 induction in rodents is selective for barbiturates and related to loss of pyridine nucleotide-dependent protective systems. J Biol Chem, 283, 17147–57
   PubMedGoogle Scholar
• Doull J, Cattley R, Elcombe C, et al. (1999). A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines. Regul Toxicol Pharmacol, 29, 327–57
   PubMed Web of Science ®Google Scholar
• Duclos S, Bride J, Ramirez LC, Bournot P. (1997). Peroxisome proliferation and beta-oxidation in Fao and MH1C1 rat hepatoma cells, HepG2 human hepatoblastoma cells and cultured human hepatocytes: effect of ciprofibrate. Eur J Cell Biol, 72, 314–23
   PubMedGoogle Scholar
• Dwivedi RS, Alvares K, Nemali MR, et al. (1989). Comparison of the peroxisome proliferator-induced pleiotropic response in the liver of nine strains of mice. Toxicol Pathol, 17, 16–26
   PubMed Web of Science ®Google Scholar
• Elcock FJ, Chipman JK, Roberts RA. (1998). The rodent nongenotoxic hepatocarcinogen and peroxisome proliferator nafenopin inhibits intercellular communication in rat but not guinea-pig hepatocytes, perturbing S-phase but not apoptosis. Arch Toxicol, 72, 439–44
   PubMed Web of Science ®Google Scholar
• Elcombe CR. (1985). Species differences in carcinogenicity and peroxisome proliferation due to trichloroethylene: a biochemical human hazard assessment. Arch Toxicol, 8, S6–17
   Google Scholar
• Elcombe CR, Bell DR, Elias E, et al. (1996). Peroxisome proliferators: species differences in response of primary hepatocytes cultures. Ann NY Acad Sci, 804, 628–35
   PubMedGoogle Scholar
• Elcombe CR, Peffer RC, Wolf DC, et al. (in press). Mode of action and human relevance analysis for nuclear receptormediated liver toxicity: a case study with phenobarbital as a model constitutive androstane receptor (CAR) activator. Crit Rev Toxicol
   Google Scholar
• Elliott BM, Elcombe CR. (1987). Lack of DNA damage or lipid peroxidation measured in vivo in the rat liver following treatment with peroxisomal proliferators. Carcinogenesis, 8, 1213–18
   PubMed Web of Science ®Google Scholar
• Escher P, Wahli W. (2000). Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res, 448, 121–38
   PubMed Web of Science ®Google Scholar
• Eveillard A, Lasserre F, de Tayrac M, et al. (2009a). Identification of potential mechanisms of toxicity after di-(2-ethylhexyl)-phthalate (DEHP) adult exposure in the liver using a systems biology approach. Toxicol Appl Pharmacol, 236, 282–92
   PubMed Web of Science ®Google Scholar
• Eveillard A, Mselli-Lakhal L, Mogha A, et al. (2009b). Di-(2-ethylhexyl)-phthalate (DEHP) activates the constitutive androstane receptor (CAR): a novel signalling pathway sensitive to phthalates. Biochem Pharmacol, 77, 1735–46
   PubMed Web of Science ®Google Scholar
• Fan CY, Pan J, Usuda N, et al. (1998). Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem, 273, 15639–45
   PubMed Web of Science ®Google Scholar
• Feige JN, Gerber A, Casals-Casas C, et al. (2010). The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms. Environ Health Perspect, 118, 234–41
   PubMedGoogle Scholar
• Fischer JG, Glauert HP, Yin T, et al. (2002). Moderate iron overload enhances lipid peroxidation in livers of rats, but does not affect NF-kappaB activation induced by the peroxisome proliferator, Wy-14 643. J Nutr, 132, 2525–31
   PubMed Web of Science ®Google Scholar
• Fitzgerald JE, Sanyer JL, Schardein JL, et al. (1981). Carcinogen bioassay and mutagenicity studies with the hypolipidemic agent gemfibrozil. J Natl Cancer Inst, 67, 1105–16
   PubMed Web of Science ®Google Scholar
• Flavell DM, Pineda Torra I, Jamshidi Y, et al. (2000). Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia, 43, 673–80
   PubMed Web of Science ®Google Scholar
• Forman BM, Chen J, Evans RM. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA, 94, 4312–7
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. (1987). Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med, 317, 1237–45
   PubMed Web of Science ®Google Scholar
• Ganning AE, Olsson MJ, Brunk U, Dallner G. (1991). Effects of prolonged treatment with phthalate ester on rat liver. Pharmacol Toxicol, 67, 392–401
   Google Scholar
• Gariot P, Barrat E, Drouin P, et al. (1987). Morphometric study of human hepatic cell modifications induced by fenofibrate. Metabolism, 36, 203–10
   PubMed Web of Science ®Google Scholar
• Gariot P, Barrat E, Mejean L, et al. (1983). Fenofibrate and human liver. Lack of proliferation of peroxisomes. Arch Toxicol, 53, 151–63
   PubMed Web of Science ®Google Scholar
• Gervois P, Torra IP, Chinetti G, et al. (1999). A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. Mol Endocrinol, 13, 1535–49
   PubMed Web of Science ®Google Scholar
• Gill JH, Roberts RA, Dive C. (1998). The nongenotoxic hepatocarcinogen nafenopin suppresses rodent hepatocyte apoptosis induced by TGFb1, DNA damage and FAS. Carcinogenesis, 19, 299–304
   PubMedGoogle Scholar
• Givler B, Alberts D, Wollenberg G, et al. (2000). TNF[alpha] is not required for Wy-14, 643-induced proliferation in mice. Toxicologist, 54, A1975
   Google Scholar
• Glauert HP, Beaty MM, Clark TD, et al. (1990). Effect of dietary vitamin E on the development of altered hepatic foci and hepatic tumors induced by the peroxisome proliferator ciprofibrate. J Cancer Res Clin Oncol, 116, 351–6
   PubMedGoogle Scholar
• Glauert HP, Eyigor A, Tharappel JC, et al. (2006). Inhibition of hepatocarcinogenesis by the deletion of the p50 subunit of NF-kappaB in mice administered the peroxisome proliferator Wy-14 643. Toxicol Sci, 90, 331–6
   PubMedGoogle Scholar
• Glauert HP, Srinivasan S, Tatum VL, et al. (1992). Effects of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cellular antioxidants and lipid peroxidation in rats. Biochem Pharmacol, 43, 1353–9
   PubMedGoogle Scholar
• Gloire G, Legrand-Poels S, Piette J. (2006). NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol, 72, 1493–505
   PubMed Web of Science ®Google Scholar
• Goel SK, Lalwani ND, Reddy JK. (1986). Peroxisome proliferation and lipid peroxidation in rat liver. Cancer Res, 46, 1324–30
   PubMed Web of Science ®Google Scholar
• Goetz ME, Luch A. (2008). Reactive species: a cell damaging rout assisting to chemical carcinogens. Cancer Lett, 266, 73–83
   PubMed Web of Science ®Google Scholar
• Goll V, Alexandre E, Viollon-Abadie C, et al. (1999). Comparison of the effects of various peroxisome proliferators on peroxisomal enzyme activities, DNA synthesis, and apoptosis in rat and human hepatocyte cultures. Toxicol Appl Pharmacol, 160, 21–32
   PubMedGoogle Scholar
• Gottlicher M, Widmark E, Li Q, Gustafsson JA. (1992). Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA, 89, 4653–7
   PubMed Web of Science ®Google Scholar
• Grasl-Kraupp B, Huber W, Just W, et al. (1993a). Enhancement of peroxisomal enzymes, cytochrome P-452 and DNA synthesis in putative preneoplastic foci of rat liver treated with the peroxisome proliferator nafenopin. Carcinogenesis, 14, 1007–12
   PubMedGoogle Scholar
• Grasl-Kraupp B, Huber W, Timmermann-Trosiener I, Schulte-Hermann R. (1993b). Peroxisomal enzyme induction uncoupled from enhanced DNA synthesis in putative preneoplastic liver foci of rats treated with a single dose of the peroxisome proliferator nafenopin. Carcinogenesis, 14, 2435–7
   PubMedGoogle Scholar
• Grasl-Kraupp B, Waldhor T, Huber W, Schulte-Hermann R. (1993c). Glutathione S-transferase isoenzyme patterns in different subtypes of enzyme-altered rat liver foci treated with the peroxisome proliferator nafenopin or with phenobarbital. Carcinogenesis, 14, 2407–12
   PubMed Web of Science ®Google Scholar
• Grasl-Kraupp B, Ruttkay-Nedecky B, Mullauer L, et al. (1997). Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology, 25, 906–12
   PubMed Web of Science ®Google Scholar
• Gray RH, de la Iglesia FA. (1984). Quantitative microscopy comparison of peroxisome proliferation by the lipid-regulating agent gemfibrozil in several species. Hepatology, 4, 520–30
   PubMed Web of Science ®Google Scholar
• Grosse Y, Baan R, Secretan-Lauby B, et al. (2011). Carcinogenicity of chemicals in industrial and consumer products, food contaminants and flavourings, and water chlorination byproducts. WHO International Agency for Research on Cancer Monograph Working Group. Lancet Oncol, 12, 328–9
   PubMed Web of Science ®Google Scholar
• Guo D, Sarkar J, Suino-Powell K, et al. (2007). Induction of nuclear translocation of constitutive androstane receptor by peroxisome proliferator-activated receptor alpha synthetic ligands in mouse liver. J Biol Chem, 282, 36766–76
   PubMed Web of Science ®Google Scholar
• Guyton KZ, Chiu WA, Bateson TF, et al. (2009). A reexamination of the PPAR-α activation mode of action as a basis for assessing human cancer risks of environmental contaminants. Environ Health Perspect, 117, 1664–72
   PubMed Web of Science ®Google Scholar
• Hager GL, Varticovski L. (2012). Chromatin in time and space. Biochim Biophys Acta, 1819, 631
   PubMedGoogle Scholar
• Hagmann M, Georgiev O, Schaffner W. (1997). The VP16 paradox: herpes simplex virus VP16 contains a long-range activation domain but within the natural multiprotein complex activates only from promoter-proximal positions. J Virol, 71, 5952–62
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646–74
   PubMed Web of Science ®Google Scholar
• Handler JA, Seed CB, Bradford BU, Thurman RG. (1992). Induction of peroxisomes by treatment with perfluorooctanoate does not increase rates of H2O2 production in intact liver. Toxicol Lett, 60, 61–8
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Kemmer C, Kadner E. (1983). Relationship between morphological changes and lipid lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis, 46, 239–46
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Kemmer C, Leonhardt W, et al. (1980). Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver. Atherosclerosis, 36, 159–72
   PubMed Web of Science ®Google Scholar
• Hanselman JC, Vartanian MA, Koester BP, et al. (2001). Expression of the mRNA encoding truncated PPAR alpha does not correlate with hepatic insensitivity to peroxisome proliferators. Mol Cell Biochem, 217, 91–7
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Fujita T, Usuda N, et al. (1999). Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem, 274, 19228–36
   PubMed Web of Science ®Google Scholar
• Hasmall SC, James NH, MacDonald N, et al. (2000a). Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARα and TNFalpha. Mutat Res, 448, 193–200
   PubMedGoogle Scholar
• Hasmall SC, James NH, MacDonald N, et al. (2000b). Species differences in response to diethylhexylphthalate: suppression of apoptosis, induction of DNA synthesis and peroxisome proliferator activated receptor alpha-mediated gene expression. Arch Toxicol, 74, 85–91
   PubMed Web of Science ®Google Scholar
• Hasmall SC, West DA, Olsen K, Roberts RA. (2000c). Role of hepatic non-parenchymal cells in the response of rat hepatocytes to the peroxisome proliferator nafenopin in vitro. Carcinogenesis, 21, 2159–65
   PubMed Web of Science ®Google Scholar
• Hasmall SC, James NH, MacDonald N, et al. (1999). Suppression of apoptosis and induction of DNA synthesis in vitro by the phthalate plasticizers monoethylhexylphthalate (MEHP) and diisononylphthalate (DINP): a comparison of rat and human hepatocytes in vitro. Arch Toxicol, 73, 451–6
   PubMed Web of Science ®Google Scholar
• Hasmall SC, James NH, Soames AR, Roberts RA. (1998). The peroxisome proliferator nafenopin does not suppress hepatocyte apoptosis in guinea-pig liver in vivo nor in human hepatocytes in vitro. Arch Toxicol, 72, 777–83
   PubMedGoogle Scholar
• Hasmall SC, Roberts RA. (2000). The nongenotoxic hepatocarcinogens diethylhexylphthalate and methylclofenapate induce DNA synthesis preferentially in octoploid rat hepatocytes. Toxicol Pathol, 28, 503–9
   PubMedGoogle Scholar
• Hays T, Rusyn I, Burns AM, et al. (2005). Role of peroxisome proliferator-activated receptor-alpha (PPARα) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis, 26, 219–27
   PubMed Web of Science ®Google Scholar
• Herren-Freund SL, Pereira MA, Khoury MD, Olson G. (1987). The carcinogenicity of trichloroethylene and its metabolites, trichloroacetic acid and dichloroacetic acid, in mouse liver. Toxicol Appl Pharmacol, 90, 183–9
   PubMed Web of Science ®Google Scholar
• Hertz R, Bishara-Shieban J, Bar-Tana J. (1995). Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem, 270, 13470–5
   PubMed Web of Science ®Google Scholar
• Hinton RH, Mitchell FE, Mann A, et al. (1986). Effects of phthalic acid esters on the liver and thyroid. Environ Health Perspect, 70, 195–210
   PubMed Web of Science ®Google Scholar
• Hoivik DJ, Qualls CW Jr, Mirabile RC, et al. (2004). Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis, 25, 1757–69
   PubMed Web of Science ®Google Scholar
• Holden P, Hasmall S, James N, et al. (2000). Tumour necrosis factor a (TNFa): role in suppression of apoptosis by peroxisome proliferators. Cell Mol Biol, 46, 29–39
   PubMed Web of Science ®Google Scholar
• Holsapple MP, Pitot HC, Cohen SM, et al. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci, 89, 51–6
   PubMed Web of Science ®Google Scholar
• Howroyd P, Swanson C, Dunn C, et al. (2004). Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARα). Toxicol Pathol, 32, 591–9
   PubMed Web of Science ®Google Scholar
• Hsieh LL, Shinozuka H, Weinstein IB. (1991). Changes in expression of cellular oncogenes and endogenous retrovirus-like sequences during hepatocarcinogenesis induced by a peroxisome proliferator. Br J Cancer, 64, 815–20
   PubMedGoogle Scholar
• Hsu MH, Savas U, Griffin KJ, Johnson EF. (2001). Identification of peroxisome proliferator responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J Biol Chem, 276, 27950–8
   PubMed Web of Science ®Google Scholar
• Huber W, Kraupp-Grasl B, Esterbauer H, Schulte-Hermann R. (1991). Role of oxidative stress in age dependent hepatocarcinogenesis by the peroxisome proliferator nafenopin in the rat. Cancer Res, 51, 1789–92
   PubMed Web of Science ®Google Scholar
• Huber WW, Grasl-Kraupp B, Stekel H, et al. (1997). Inhibition instead of enhancement of lipid peroxidation by pretreatment with the carcinogenic peroxisome proliferator nafenopin in rat liver exposed to a high single dose of corn oil. Arch Toxicol, 71, 575–81
   PubMedGoogle Scholar
• Huttunen JK, Heinonen OP, Manninen V, et al. (1994). The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med, 235, 31–9
   PubMed Web of Science ®Google Scholar
• IARC. (1996). Some pharmaceutical drugs. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Lyon, France: IARC Press, 391–426
   Google Scholar
• IARC. (2012). Some chemicals present in industrial and consumer products, food and drinking-water. IARC Technical Report No. 101. Lyon, France: IARC Press
   Google Scholar
• Isenberg JS, Kamendulis LM, Ackley DC, et al. (2001). Reversibility and persistence of di-2-ethylhexyl phthalate (DEHP)- and phenobarbital-induced hepatocellular changes in rodents. Toxicol Sci, 64, 192–9
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Kamendulis LM, Smith JH, et al. (2000). Effects of Di-2-ethylhexyl phthalate (DEHP) on gap-junctional intercellular communication (GJIC), DNA synthesis, and peroxisomal beta oxidation (PBOX) in rat, mouse, and hamster liver. Toxicol Sci, 56, 73–85
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Kolaja KL, Ayoubi SA, et al. (1997). Inhibition of WY 14 643-induced hepatic lesion growth in mice by rotenone. Carcinogenesis, 18, 1511–9
   PubMedGoogle Scholar
• Issemann I, Green S. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 347, 645–50
   PubMed Web of Science ®Google Scholar
• Ito Y, Yamanoshita O, Asaeda N, et al. (2007). Di(2-ethylhexyl)phthalate induces hepatic tumorigenesis through a peroxisome proliferator-activated receptor alpha-independent pathway. J Occup Health, 49, 172–82
   PubMed Web of Science ®Google Scholar
• James NH, Gill JH, Brindle R, et al. (1998a). Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis. Toxicol Lett, 102–103, 91–6
   PubMedGoogle Scholar
• James NH, Soames AR, Roberts RA. (1998b). Suppression of hepatocyte apoptosis and induction of DNA synthesis by the rat and mouse hepatocarcinogen diethylhexylphthalate (DEHP) and the mouse hepatocarcinogen 1,4-dichlorobenzene (DCB). Arch Toxicol, 72, 784–90
   PubMed Web of Science ®Google Scholar
• James NH, Roberts RA. (1996). Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. Carcinogenesis, 17, 1623–32
   PubMed Web of Science ®Google Scholar
• Janssen-Timmen U, Traub O, Dermietzel R, et al. (1986). Reduced number of gap junctions in rat hepatocarcinomas detected by monoclonal antibody. Carcinogenesis, 7, 1475–82
   PubMed Web of Science ®Google Scholar
• Jia Y, Guo GL, Surapureddi S, et al. (2005). Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity. Proc Natl Acad Sci, 102, 12531–6
   PubMed Web of Science ®Google Scholar
• Jia Y, Qi C, Zhang Z, et al. (2003). Overexpression of peroxisome proliferator-activated receptor-alpha (PPARα)-regulated genes in liver in the absence of peroxisome proliferation in mice deficient in both L- and D-forms of enoyl-CoA hydratase/dehydrogenase enzymes of peroxisomal beta-oxidation system. J Biol Chem, 278, 47232–9
   PubMedGoogle Scholar
• Julien E, Boobis AR, Olin SS. (2009). The key events dose-response framework: a cross-disciplinary mode-of-action based approach to examining dose-response and thresholds. Crit Rev Food Sci Nutr, 49, 682–9
   PubMed Web of Science ®Google Scholar
• Kamendulis LM, Isenberg JS, Prow TW, Klaunig JE. (1997). Rotenone reversal of Wy-14 643-induced inhibition of hepatic gap junctional intercellular communication. Toxicologist, 36, 58
   Google Scholar
• Kamendulis LM, Isenberg JS, Smith JH, et al. (2002). Comparative effects of phthalate monoesters on gap junctional intercellular communication and peroxisome proliferation in rodent and primate hepatocytes. J Toxicol Environ Health A, 65, 569–88
   PubMed Web of Science ®Google Scholar
• Karin M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature, 441, 431–6
   PubMed Web of Science ®Google Scholar
• Kasai H. (1997). Analysis of a form of oxidative DNA damage, 8-hydroxy-2-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res, 387, 147–63
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Suzuki S, Kozuka H, et al. (1994). Effects of prolonged administration of perfluorooctanoic acid on hepatic activities of enzymes which detoxify peroxide and xenobiotic in the rat. Toxicology, 93, 85–97
   PubMedGoogle Scholar
• Keller H, Devchand PR, Perroud M, Wahli W. (1997). PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol Chem, 378, 651–5
   PubMed Web of Science ®Google Scholar
• Keller H, Dreyer C, Medin J, et al. (1993). Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci, 90, 2160–4
   PubMed Web of Science ®Google Scholar
• Kersten S, Seydoux J, Peters JM, et al. (1999). Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J Clin Inv, 103, 1489–98
   PubMed Web of Science ®Google Scholar
• Ketcham CA, Klaunig JE. (1997). The inhibition of gap junctional intercellular communication by WY-14 643 through the activation of protein kinase c and oxidative stress. Toxicologist, 36, 223
   Google Scholar
• Khetchoumian K, Teletin M, Tisserand J, et al. (2008). Trim24 (Tif1 alpha): an essential ‘brake’ for retinoic acid-induced transcription to prevent liver cancer. Cell Cycle, 7, 3647–52
   PubMed Web of Science ®Google Scholar
• Kim MY, Song KS, Park GH, et al. (2004). B6C3F1 mice exposed to ozone with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone and/or dibutyl phthalate showed toxicities through alterations of NF-kappaB, AP-1, Nrf2, and osteopontin. J Vet Sci, 5, 131–7
   PubMedGoogle Scholar
• Klaunig JE, Babich MA, Baetcke KP, et al. (2003). PPARα agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol, 33, 655–780
   PubMed Web of Science ®Google Scholar
• Klaunig JE, Hocevar BA, Kamendulis LM. (2012). Mode of action analysis of perfluorooctanoic acid (PFOA) tumorigenicity and human relevance. Reprod Toxicol, 33, 410--18
   Google Scholar
• Klaunig JE, Ruch RJ. (1990). Role of inhibition of intercellular communication in carcinogenesis. Lab Invest, 62, 135–46
   PubMed Web of Science ®Google Scholar
• Klaunig JE, Ruch RJ, Weghorst CM. (1990). Comparative effects of phenobarbital, DDT, and lindane on mouse hepatocyte gap-junctional intercellular communication. Toxicol Appl Pharmacol, 102, 553–63
   PubMed Web of Science ®Google Scholar
• Klaunig JE, Ruch RJ, DeAngelo AB, Kaylor WH. (1988). Inhibition of mouse hepatocyte intercellular communication by phthalate monoesters. Cancer Lett, 43, 65–71
   PubMed Web of Science ®Google Scholar
• Klaunig JE, Ruch RJ, Lin ELC. (1989). Effects of trichloroethylene and its metabolites on rodent hepatocyte intercellular communication. Toxicol Appl Pharmacol, 99, 454–65
   PubMed Web of Science ®Google Scholar
• Klaunig JE, Xu Y, Isenberg JS, et al. (1998). The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect, 106, 289–95
   PubMed Web of Science ®Google Scholar
• Kluwe WM, Huff JE, Matthews HB, et al. (1985). Comparative chronic toxicities and carcinogenic potentials of 2-ethylhexyl-containing compounds in rats and mice. Carcinogenesis, 6, 1577–83
   PubMedGoogle Scholar
• Kluwe WM, McConnell EE, Huff JE, et al. (1982). Carcinogenicity testing of phthalate esters and related compounds. Environ Health Perspect, 45, 129–33, 1982
   PubMed Web of Science ®Google Scholar
• Krause BR, Bousley R, Kieft K, et al. (1994). Comparison of lifibrol to other lipid-regulating agents in experimental animals. Pharmacol Res, 29, 345–57
   PubMedGoogle Scholar
• Lacquemant C, Lepretre F, Pineda Torra I, et al. (2000). Mutation screening of the PPARα gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab, 26, 393–401
   PubMedGoogle Scholar
• Lake BG, Evans JG, Cunninghame ME, Price RJ. (1993). Comparison of the hepatic effects of nafenopin and WY-14 643 on peroxisome proliferation and cell replication in the rat and Syrian hamster. Environ Health Perspect, 101, 241–7
   PubMedGoogle Scholar
• Lake BG, Evans JG, Gray TJ, et al. (1989a). Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset. Toxicol Appl Pharmacol, 99, 148–60
   PubMed Web of Science ®Google Scholar
• Lake BG, Gray TJ, Körösi SA, Walters DG. (1989b). Nafenopin, a peroxisome proliferator, depletes hepatic vitamin E content and elevates plasma oxidised glutathione levels in rats. Toxicol Lett., 45, 221–9
   PubMedGoogle Scholar
• Lake BG, Kozlen SL, Evans JG, et al. (1987). Effect of prolonged administration of clofibric acid and di-(2-ethylhexyl)phthalate on hepatic enzyme activities and lipid peroxidation in the rat. Toxicology, 44, 213–28
   PubMed Web of Science ®Google Scholar
• Lake BG, Rumsby PC, Price RJ, Cunninghame ME. (2000). Species differences in hepatic peroxisome proliferation, cell replication and transforming growth factor-beta1 gene expression in the rat, Syrian hamster and guinea pig. Mutat Res, 448, 213–25
   PubMedGoogle Scholar
• Lalwani ND, Reddy MK, Qureshi SA, et al. (1983). Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in the rat liver. Hum Toxicol, 2, 27–48
   PubMedGoogle Scholar
• Lapinskas PJ, Brown S, Leesnitzer LM, et al. (2005). Role of PPARalpha in mediating the effects of phthalates and metabolites in the liver. Toxicology, 207, 149–63
   PubMed Web of Science ®Google Scholar
• Laughter AR, Dunn CS, Swanson CL, et al. (2004). Role of the peroxisome proliferator-activated receptor alpha (PPARα) in responses to trichloroethylene and metabolites, trichloroacetate and dichloroacetate in mouse liver. Toxicology, 203, 83–98
   PubMed Web of Science ®Google Scholar
• Lawrence JW, Li Y, Chen S, et al. (2001a). Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J Biol Chem, 276, 31521–7
   PubMed Web of Science ®Google Scholar
• Lawrence JW, Wollenberg GK, DeLuca JG. (2001b). Tumor necrosis factor alpha is not required for WY14 643-induced cell proliferation. Carcinogenesis, 22, 381–6
   PubMedGoogle Scholar
• Lee SS, Pineau T, Drago J, et al. (1995). Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol, 15, 3012–22
   PubMed Web of Science ®Google Scholar
• Li Y, Glauert HP, Spear BT. (2000a). Activation of nuclear factor-kappaB by the peroxisome proliferator ciprofibrate in H4IIEC3 rat hepatoma cells and its inhibition by the antioxidants N-acetylcysteine and vitamin E. Biochem Pharmacol, 59, 427–34
   PubMed Web of Science ®Google Scholar
• Li Y, Tharappel JC, Cooper S, et al. (2000b). Expression of the hydrogen peroxide-generating enzyme fatty acyl CoA oxidase activates NF-kappaB. DNA Cell Biol, 19, 113–20
   PubMedGoogle Scholar
• Li Y, Kovach A, Suino-Powell K, et al. (2008). Structural and biochemical basis for the binding selectivity of peroxisome proliferator-activated receptor gamma to PGC-1alpha. J Biol Chem, 283, 19132–9
   PubMedGoogle Scholar
• Li Y, Leung LK, Glauert HP, Spear BT. (1996). Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-kappa B activity. Carcinogenesis, 17, 2305–9
   PubMed Web of Science ®Google Scholar
• Lington AW, Khalimi GH, Klaunig JE, Nikiforov AI. (1994). Effects of di-2-ethylhexyl phthalate and four metabolites on rodent hepatocyte gap-junctional intercellular communication. Toxicologist, 14, 57
   Google Scholar
• Liu MH, Li J, Shen P, et al. (2008). A natural polymorphism in peroxisome proliferator-activated receptor-alpha hinge region attenuates transcription due to defective release of nuclear receptor corepressor from chromatin. Mol Endocrinol, 22, 1078–92
   PubMedGoogle Scholar
• Loewenstein WR, Kanno Y. (1966). Intercellular communication and the control of tissue growth: lack of communication between cancer cells. Nature, 209, 1248–9
   PubMed Web of Science ®Google Scholar
• Lu Y, Boekschoten MV, Wopereis S, et al. (2011). Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice. Physiol Genomics, 43, 1307–18
   PubMedGoogle Scholar
• Luebker DJ, Hansen KJ, Bass NM, et al. (2002). Interactions of fluorochemicals with rat liver fatty acid-binding protein. Toxicology, 176, 175–85
   PubMed Web of Science ®Google Scholar
• Ma WL, Hsu CL, Wu MH, et al. (2008). Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology, 135, 947–55, 955
   PubMed Web of Science ®Google Scholar
• MacDonald N, Holden PR, Roberts RA. (1999). Addition of peroxisome proliferator-activated receptor alpha to guinea pig hepatocytes confers increased responsiveness to peroxisome proliferators. Cancer Res, 59, 4776–80
   PubMedGoogle Scholar
• Maeda S, Kamata H, Luo JL, et al. (2005). IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell, 121, 977–90
   PubMed Web of Science ®Google Scholar
• Maglich JM, Lobe DC, Moore JT. (2009). The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. J Lipid Res, 50, 439–45
   PubMed Web of Science ®Google Scholar
• Mäkinen J, Frank C, Jyrkkärinne J, et al. (2002). Modulation of mouse and human phenobarbital-responsive enhancer module by nuclear receptors. Mol Pharmacol, 62, 366–78
   PubMed Web of Science ®Google Scholar
• Makowska JM, Gibson GG, Bonner FW. (1992). Species differences in ciprofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation. J Biochem Toxicol, 7, 183–91
   PubMedGoogle Scholar
• Mally A, Chipman JK. (2002). Non-genotoxic carcinogens: early effects on gap junctions, cell proliferation and apoptosis in the rat. Toxicology, 180, 233–24
   PubMed Web of Science ®Google Scholar
• Maloney EK, Waxman DJ. (1999). Trans-activation of PPARα and PPARgamma by structurally diverse environmental chemicals. Toxicol Appl Pharmacol, 161, 209–18
   PubMed Web of Science ®Google Scholar
• Marsman D. (1995). NTP technical report on the toxicity studies of dibutyl phthalate (CAS No. 84-74-2) administered in feed to F344/N rats and B6C3F1 mice. Toxic Rep Ser, 30, 1–G5
   PubMedGoogle Scholar
• Marsman DS, Cattley RC, Conway JG, Popp JA. (1988). Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14 643) in rats. Cancer Res, 48, 6739–44
   PubMed Web of Science ®Google Scholar
• Marsman DS, Goldsworthy TL, Popp JA. (1992). Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14 643 and clofibric acid. Carcinogenesis, 13, 1011–7
   PubMed Web of Science ®Google Scholar
• Marsman DS, Popp JA. (1994). Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisome proliferator, Wy-14 643. Carcinogenesis, 15, 111–7
   PubMed Web of Science ®Google Scholar
• Martin PG, Guillou H, Lasserre F, et al. (2007). Novel aspects of PPARα-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study. Hepatology, 45, 767–77
   PubMedGoogle Scholar
• Maruyama H, Amanuma T, Tsutsumi M, et al. (1994). Inhibition by catechol and di(2-ethylhexyl)phthalate of pancreatic carcinogenesis after initiation with N-nitrosobis(2-hydroxypropyl)amine in Syrian hamsters. Carcinogenesis, 15, 1193–6
   PubMedGoogle Scholar
• Mascaro C, Acosta E, Ortiz JA, et al. (1998). Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator activated receptor. J Biol Chem, 273, 8560–3
   PubMed Web of Science ®Google Scholar
• McGuire EJ, Lucas JA, Gray RH, de la Iglesia FA. (1991). Peroxisome induction potential and lipid-regulating activity in rats. Quantitative microscopy and chemical structure-activity relationships. Am J Pathol, 139, 217–29
   PubMedGoogle Scholar
• McNally JG, Muller WG, Walker D, et al. (2000). The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science, 287, 1262–5
   PubMed Web of Science ®Google Scholar
• Meek ME. (2008). Recent developments in frameworks to consider human relevance of hypothesized modes of action for tumours in animals. Environ Mol Mutagen, 49, 110–6
   PubMed Web of Science ®Google Scholar
• Meek ME, Bucher JR, Cohen SM, et al. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol, 33, 591–653
   PubMed Web of Science ®Google Scholar
• Melnick RL, Brody C, DiGangi J, Huff J. (2003). The IARC evaluation of DEHP excludes key papers demonstrating carcinogenic effects. Int J Occup Environ Health, 9, 400–2
   PubMed Web of Science ®Google Scholar
• Menegazzi M, Carcereri-De Prati A, Suzuki H, et al. (1997). Liver cell proliferation induced by nafenopin and cyproterone acetate is not associated with increases in activation of transcription factors NF-kappaB and AP-1 or with expression of tumor necrosis factor alpha. Hepatology, 25, 585–92
   PubMed Web of Science ®Google Scholar
• Meyer K, Lee JS, Dyck PA, et al. (2003). Molecular profiling of hepatocellular carcinomas developing spontaneously in acyl-CoA oxidase deficient mice: comparison with liver tumors induced in wild-type mice by a peroxisome proliferator and a genotoxic carcinogen. Carcinogenesis, 24, 975–84
   PubMed Web of Science ®Google Scholar
• Mitchell FE, Price SC, Hinton RH, et al. (1985). Time and dose-response study of the effects on rats of the plasticizer di(2-ethylhexyl) phthalate. Toxicol Appl Pharmacol, 81, 371–92
   PubMed Web of Science ®Google Scholar
• Moennikes O, Stahl S, Bannasch P, et al. (2003). WY-14 643-mediated promotion of hepatocarcinogenesis in connexin32-wild-type and connexin32-null mice. CarcinogenesisSep, 24, 1561–5
   PubMedGoogle Scholar
• Morimura K, Cheung C, Ward JM, et al. (2006). Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14 643-induced liver tumorigenesis. Carcinogenesis, 27, 1074–80
   PubMed Web of Science ®Google Scholar
• Mukherjee R, Jow L, Noonan D, McDonnell DP. (1994). Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Molec Biol, 51, 157–66
   PubMed Web of Science ®Google Scholar
• National Toxicology Program (NTP). (1982). Carcinogenesis bioassay of di(2-ethylhexyl)phthalate (CAS No. 117-81-7) in F344 rats and B6C3F1 mice (feed studies). Natl Toxicol Program Tech Rep Ser, 217, 1–127
   PubMedGoogle Scholar
• Nemali MR, Usuda N, Reddy MK, et al. (1988). Comparison of constitutive and inducible levels of expression of peroxisomal beta-oxidation and catalase genes in liver and extrahepatic tissues of rat. Cancer Res, 48, 5316–24
   PubMed Web of Science ®Google Scholar
• Nesfield SR, Clarke CJ, Hoivik DJ, et al. (2005a). Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse. Int J Toxicol, 24, 301–11
   PubMed Web of Science ®Google Scholar
• Nesfield SR, Williams TC, Hoivik DJ, et al. (2005b). Evaluation of the carcinogenic potential of clofibrate in the neonatal mouse. Int J Toxicol, 24, 341–8
   PubMedGoogle Scholar
• Neveu MJ, Hully JR, Paul DL, Pitot HC. (1990). Reversible alteration in the expression of the gap-junctional protein connexin 32 during tumor promotion in rat liver and its role during cell proliferation. Cancer Commun, 2, 21–31
   PubMed Web of Science ®Google Scholar
• Nicholls-Grzemski FA, Belling GB, Priestly BG, et al. (2000). Clofibrate pretreatment in mice confers resistance against hepatic lipid peroxidation. J Biochem Mol Toxicol, 14, 335–45
   PubMedGoogle Scholar
• Nilakantan V, Spear BT, Glauert HP. (1998). Liver-specific catalase expression in transgenic mice inhibits NF-kappaB activation and DNA synthesis induced by the peroxisome proliferator ciprofibrate. Carcinogenesis, 19, 631–7
   PubMedGoogle Scholar
• O’Brien ML, Cunningham ML, Spear BT, Glauert HP. (2001a). Effects of peroxisome proliferators on glutathione and glutathione-related enzymes in rats and hamsters. Toxicol Appl Pharmacol, 171, 27–37
   PubMedGoogle Scholar
• O’Brien ML, Twaroski TP, Cunningham ML, et al. (2001b). Effects of peroxisome proliferators on antioxidant enzymes and antioxidant vitamins in rats and hamsters. Toxicol Sci, 60, 271–8
   PubMedGoogle Scholar
• Oberhammer FA, Qin HM. (1995). Effect of three tumour promoters on the stability of hepatocytes cultures and apoptosis after transforming growth factor-beta1. Carcinogenesis, 16, 1363–71
   PubMedGoogle Scholar
• Ohmura T, Ledda-Columbano GM, Piga R, et al. (1996). Hepatocyte proliferation induced by a single dose of a peroxisome proliferator. Am J Pathol, 148, 815–24
   PubMed Web of Science ®Google Scholar
• Pacot C, Petit M, Rollin M, et al. (1996). Difference between guinea pig and rat in the liver peroxisomal response to equivalent plasmatic level of ciprofibrate. Arch Biochem Biophys, 327, 181–8
   PubMedGoogle Scholar
• Palmer CN, Hsu MH, Griffin KJ, et al. (1998). Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol, 53, 14–22
   PubMed Web of Science ®Google Scholar
• Parzefall W, Berger W, Kainzbauer E, et al. (2001). Peroxisome proliferators do not increase DNA synthesis in purified rat hepatocytes. Carcinogenesis, 22, 519–23
   PubMedGoogle Scholar
• Patsouris D, Reddy JK, Müller M, Kersten S. (2006). Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology, 147, 1508–16
   PubMed Web of Science ®Google Scholar
• Permadi H, Lundgren B, Andersson K, et al. (1993). Effects of perfluoro fatty acids on peroxisome proliferation and mitochondrial size in mouse liver: dose and time factors and effect of chain length. Xenobiotica, 23, 761–70
   PubMed Web of Science ®Google Scholar
• Perrone CE, Shao L, Williams GM. (1998). Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicol Appl Pharmacol, 150, 277–86
   PubMed Web of Science ®Google Scholar
• Peters JM, Aoyama T, Cattley RC, et al. (1998). Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver. Carcinogenesis, 19, 1989–94
   PubMed Web of Science ®Google Scholar
• Peters JM, Cattley RC, Gonzalez FJ. (1997). Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14 643. Carcinogenesis, 18, 2029–33
   PubMed Web of Science ®Google Scholar
• Peters JM, Cheung C, Gonzalez FJ. (2005). Peroxisome proliferator-activated receptor-α and liver cancer: where do we stand? J Mol Med, 83, 774–85
   PubMed Web of Science ®Google Scholar
• Peters JM, Rusyn I, Rose ML, et al. (2000). Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis, 21, 823–6
   PubMed Web of Science ®Google Scholar
• Plant NJ, Horley NJ, Dickins M, et al. (1998). The coordinate regulation of DNA synthesis and suppression of apoptosis is differentially regulated by the liver growth agents, phenobarbital and methylclofenapate. Carcinogenesis, 19, 1521–7
   PubMedGoogle Scholar
• Price RJ, Evans JG, Lake BG. (1992). Comparison of the effects of nafenopin on hepatic peroxisome proliferation and replicative DNA synthesis in the rat and Syrian hamster. Food Chem Toxicol, 30, 937–44
   PubMed Web of Science ®Google Scholar
• Pugh G Jr, Isenberg JS, Kamendulis LM, et al. (2000). Effects of diisononyl phthalate, di-2-ethylhexyl phthalate, and clofibrate in cynomolgus monkeys. Toxicol Sci, 56, 181–8
   PubMed Web of Science ®Google Scholar
• Qu A, Shah YM, Matsubara T, et al. (2010). PPARalpha-dependent activation of cell cycle control and DNA repair genes in hepatic nonparenchymal cells. Toxicol Sci, 118, 404–10
   PubMedGoogle Scholar
• Qu B, Halliwell B, Ong CN, et al. (2000). Caloric restriction prevents oxidative damage induced by the carcinogen clofibrate in mouse liver. FEBS Lett, 473, 85–8
   PubMedGoogle Scholar
• Qu B, Li Q, Wong KP, et al. (2001). Mechanism of clofibrate hepatotoxicity: mitochondrial damage and oxidative stress in hepatocytes. Free Radical Biol Med, 31, 659–69
   PubMed Web of Science ®Google Scholar
• Rakhshandehroo M, Hooiveld G, Müller M, Kersten S. (2009). Comparative analysis of gene regulation by the transcription factor PPARα between mouse and human. PLoS One, 4, e6796
   PubMed Web of Science ®Google Scholar
• Rao MS, Dwivedi RS, Subbarao V, Reddy JK. (1988). Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound. Br J Cancer, 58, 46–51
   PubMedGoogle Scholar
• Rao MS, Lalwani ND, Scarpelli DG, Reddy JK. (1982). The absence of gamma-glutamyl transpeptidase activity in putative preneoplastic lesions and in hepatocellular carcinomas induced in rats by the hypolipidemic peroxisome proliferator Wy-14 643. Carcinogenesis, 3, 1231–3
   PubMed Web of Science ®Google Scholar
• Rao MS, Lalwani ND, Watanabe TK, Reddy JK. (1984). Inhibitory effect of antioxidants ethoxyquin and 2-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator. Cancer Res, 44, 1072–6
   PubMed Web of Science ®Google Scholar
• Rao MS, Reddy JK. (1996). Hepatocarcinogenesis of peroxisome proliferators. Ann N Y Acad Sci, 804, 573–87
   PubMed Web of Science ®Google Scholar
• Rao MS, Subbarao V. (1997). The effect of deferoxamine on ciprofibrate-induced hepatocarcinogenesis in the rat. In Vivo, 11, 495–8
   PubMedGoogle Scholar
• Rao MS, Subbarao V. (1999). Inhibition of ciprofibrate-induced hepatocarcinogenesis in the rat by dimethylthiourea, a scavenger of hydroxyl radical. Oncol Rep, 6, 1285–8
   PubMedGoogle Scholar
• Rao MS, Tatematsu M, Subbarao V, et al. (1986). Analysis of peroxisome proliferator-induced preneoplastic and neoplastic lesions of rat liver for placental form of glutathione S-transferase and gamma-glutamyltranspeptidase. Cancer Res, 46, 5287–90
   PubMed Web of Science ®Google Scholar
• Rao MS, Thangada S, Subbarao V. (1991). Peroxisome proliferation in neoplastic nodules and hepatocellular carcinomas induced by ciprofibrate in the rat. Exp Pathol, 41, 44–9
   PubMedGoogle Scholar
• Rao MS, Usuda N, Subbarao V, Reddy JK. (1987). Absence of gamma-glutamyl transpeptidase activity in neoplastic lesions induced in the liver of male F-344 rats by di-(2-ethylhexyl)phthalate, a peroxisome proliferator. Carcinogenesis, 8, 1347–50
   PubMed Web of Science ®Google Scholar
• Reddy JK, Lalwani ND, Reddy MK, Qureshi SA. (1982). Excessive accumulation of autofluorescent lipofuscin in the liver during hepatocarcinogenesis by methyl clofenapate and other hypolipidemic peroxisome proliferators. Cancer Res, 42, 259–66
   PubMed Web of Science ®Google Scholar
• Reddy JK, Qureshi SA. (1979). Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-alpha-p-chlorophenoxyisobutyrate (clofibrate) in rats. Br J Cancer, 40, 476–82
   PubMed Web of Science ®Google Scholar
• Reddy JK, Rao MS, Azarnoff DL, Sell S. (1979). Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. Cancer Res, 39, 152–61
   PubMed Web of Science ®Google Scholar
• Reddy JK, Rao MS. (1977). Malignant tumors in rats fed nafenopin, a hepatic peroxisome proliferator. J Natl Cancer Inst, 59, 1645–50
   PubMed Web of Science ®Google Scholar
• Reddy JK, Rao MS. (1989). Oxidative DNA damage caused by persistent peroxisome proliferation: its role in hepatocarcinogenesis. Mutat Res, 214, 63–8
   PubMed Web of Science ®Google Scholar
• Ren H, Aleksunes LM, Wood C, et al. (2010). Characterization of peroxisome proliferator-activated receptor alpha-independent effects of PPARalpha activators in the rodent liver: di-(2-ethylhexyl) phthalate also activates the constitutive-activated receptor. Toxicol Sci, 113, 45–59
   PubMed Web of Science ®Google Scholar
• Ren H, Vallanat B, Nelson DM, et al. (2009). Evidence for the involvement of xenobiotic-responsive nuclear receptors in transcriptional effects upon perfluoroalkyl acid exposure in diverse species. Reprod Toxicol, 27, 266–77
   PubMed Web of Science ®Google Scholar
• Richert L, Lamboley C, Viollon-Abadie C, et al. (2003). Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. Toxicol Appl Pharmacol, 191, 130–46
   PubMed Web of Science ®Google Scholar
• Roberts RA, Ganey PE, Ju C, et al. (2007). Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci, 96, 2–15
   PubMed Web of Science ®Google Scholar
• Roberts RA, James NH, Hasmall SC, et al. (2000). Apoptosis and proliferation in nongenotoxic carcinogenesis: species differences and role of PPARα. Toxicol Lett, 112–113, 49–57
   PubMed Web of Science ®Google Scholar
• Roberts RA. (1999). Peroxisome proliferators: mechanisms of adverse effects in rodents and molecular basis for species differences. Arch Toxicol, 73, 413–8
   PubMed Web of Science ®Google Scholar
• Roglans N, Bellido A, Rodriguez C, et al. (2002). Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. Clin Pharmacol Ther, 72, 692–701
   PubMed Web of Science ®Google Scholar
• Rolfe M, James NH, Roberts RA. (1997). Tumour necrosis factor alpha (TNF-alpha) suppresses apoptosis and induces S-phase in rodent hepatocytes: a mediator of the hepatocarcinogenicity of peroxisome proliferators? Carcinogenesis, 18, 2277–80
   PubMed Web of Science ®Google Scholar
• Rose ML, Cattley RC, Dunn C, et al. (1999a). Dietary glycine prevents the development of liver tumors caused by the peroxisome proliferator WY-14 643. Carcinogenesis, 20, 2075–81
   PubMedGoogle Scholar
• Rose ML, Rivera CA, Bradford BU, et al. (1999b). Kupffer cell oxidant production is central to the mechanism of peroxisome proliferators. Carcinogenesis, 20, 27–33
   PubMed Web of Science ®Google Scholar
• Rose ML, Germolec D, Arteel GE, et al. (1997a). Dietary glycine prevents increases in hepatocyte proliferation caused by the peroxisome proliferator WY-14 643. Chem Res Toxicol, 10, 1198–204
   PubMed Web of Science ®Google Scholar
• Rose ML, Germolec DR, Schoonhoven R, Thurman RG. (1997b). Kupffer cells are causally responsible for the mitogenic effect of peroxisome proliferators. Carcinogenesis, 18, 1453–6
   PubMed Web of Science ®Google Scholar
• Rose ML, Rusyn I, Bojes HK, et al. (2000). Role of Kupffer cells and oxidants in signaling peroxisome proliferator-induced hepatocyte proliferation. Mutat Res, 448, 179–92
   PubMed Web of Science ®Google Scholar
• Rosen MB, Abbott BD, Wolf DC, et al. (2008a). Gene profiling in the livers of wild-type and PPARα-null mice exposed to perfluorooctanoic acid. Toxicol Pathol, 36, 592–607
   PubMed Web of Science ®Google Scholar
• Rosen MB, Lee JS, Ren H, et al. (2008b). Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPAR alpha and CAR. Toxicol Sci, 103, 46–56
   PubMed Web of Science ®Google Scholar
• Rosen MB, Schmid JR, Corton JC, et al. (2010). Gene expression profiling in wild-type and PPARα-null mice exposed to perfluorooctane sulfonate reveals PPARα-independent effects. PPAR Res, 2010, Article ID, 794739. 1--23
   Google Scholar
• Roy D, Cai Q, Felty Q, Narayan S. (2007). Estrogen-induced generation of reactive oxygen and nitrogen species, gene damage, and estrogen-dependent cancers. J Toxicol Environ Health B Crit Rev, 10, 235–57
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med, 341, 410--18
   Google Scholar
• Ruch RJ, Klaunig JE. (1988). Kinetics of phenobarbital inhibition of intercellular communication in mouse hepatocytes. Cancer Res, 48, 2519–23
   PubMed Web of Science ®Google Scholar
• Rusyn I, Asakura S, Pachkowski B, et al. (2004). Expression of base excision DNA repair genes is a sensitive biomarker for in vivo detection of chemical-induced chronic oxidative stress: identification of the molecular source of radicals responsible for DNA damage by peroxisome proliferators. Cancer Res, 64, 1050–7
   PubMed Web of Science ®Google Scholar
• Rusyn I, Corton JC. (2012). Mechanistic considerations for human relevance of cancer hazard of di(2-ethylhexyl) phthalate. Mutat Res, 750, 141--58
   Google Scholar
• Rusyn I, Kadiiska MB, Dikalova A, et al. (2001). Phthalates rapidly increase production of reactive oxygen species in vivo: role of Kupffer cells. Mol Pharmacol, 59, 744–50
   PubMed Web of Science ®Google Scholar
• Rusyn I, Peters JM, Cunningham ML. (2006). Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver. Crit Rev Toxicol, 36, 459–79
   PubMed Web of Science ®Google Scholar
• Rusyn I, Tsukamoto H, Thurman RG. (1998). WY-14 643 rapidly activates nuclear factor kappaB in Kupffer cells before hepatocytes. Carcinogenesis, 19, 1217–22
   PubMedGoogle Scholar
• Rusyn I, Yamashina S, Segal BH, et al. (2000). Oxidants from nicotinamide adenine dinucleotide phosphate oxidase are involved in triggering cell proliferation in the liver due to peroxisome proliferators. Cancer Res, 60, 4798–803
   PubMed Web of Science ®Google Scholar
• Sanderson LM, de Groot PJ, Hooiveld GJ, et al. (2008). Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics. PLoS One, 3, e1681
   PubMed Web of Science ®Google Scholar
• Sapone A, Peters JM, Sakai S, et al. (2000). The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics, 10, 321–33
   PubMedGoogle Scholar
• Sausen PJ, Lee DC, Rose ML, Cattley RC. (1995). Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: relationship to mitochondrial alterations. Carcinogenesis, 16, 1795–801
   PubMedGoogle Scholar
• Schmezer P, Pool BL, Klein RG, et al. (1988). Various short-term assays and two long-term studies with the plasticizer di(2-ethylhexyl)phthalate in the Syrian golden hamster. Carcinogenesis, 9, 37–43
   PubMed Web of Science ®Google Scholar
• Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. (1996a). PPARα and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J, 15, 5336–48
   PubMed Web of Science ®Google Scholar
• Schoonjans K, Staels B, Auwerx J. (1996b). The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta, 1302, 93–109
   PubMed Web of Science ®Google Scholar
• Schulte-Hermann R, Ohde G, Schuppler J, Timmermann-Trosiener I. (1981). Enhanced proliferation of putative preneoplastic cells in rat liver following treatment with the tumor promoters phenobarbital, hexachlorocyclohexane, steroid compounds, and nafenopin. Cancer Res, 41, 2556–62
   PubMed Web of Science ®Google Scholar
• Schwarz JJ, Chakraborty T, Martin J, et al. (1992). The basic region of myogenin cooperates with two transcription activation domains to induce muscle-specific transcription. Mol Cell Biol, 12, 266–75
   PubMedGoogle Scholar
• Seed J, Carney EW, Corley RA, et al. (2005). Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol, 35, 664–72
   PubMed Web of Science ®Google Scholar
• Seo KW, Kim KB, Kim YJ, et al. (2004). Comparison of oxidative stress and changes of xenobiotic metabolizing enzymes induced by phthalates in rats. Food Chem Toxicol, 42, 107–14
   PubMedGoogle Scholar
• Shah YM, Morimura K, Yang Q, et al. (2007). Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol, 27, 4238–47
   PubMed Web of Science ®Google Scholar
• Shaw D, Lee R, Roberts RA. (2002). Species differences in response to the phthalate plasticizer monoisononylphthalate (MINP) in vitro: a comparison of rat and human hepatocytes. Arch Toxicol, 76, 344–50
   PubMedGoogle Scholar
• Sher T, Yi HF, McBride OW, Gonzalez FJ. (1993). cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry, 32, 5598–604
   PubMed Web of Science ®Google Scholar
• Shipley JM, Hurst CH, Tanaka SS, et al. (2004). trans-activation of PPARα and induction of PPARα target genes by perfluorooctane-based chemicals. Toxicol Sci, 80, 151–60
   PubMed Web of Science ®Google Scholar
• Smith-Oliver T, Butterworth BE. (1987). Correlation of the carcinogenic potential of di(2-ethylhexyl)phthalate (DEHP) with induced hyperplasia rather than with genotoxic activity. Mutat Res, 188, 21–8
   PubMed Web of Science ®Google Scholar
• Soames AR, Cliffe S, Pate I, Foster JR. (1999). Quantitative analysis of the lobular distribution of S-phase in rat liver following dietary administration of di(2-ethylhexyl)phthalate. Toxicol Pathol, 27, 436–40
   PubMedGoogle Scholar
• Soliman MS, Cunningham ML, Morrow JD, et al. (1997). Evidence against peroxisome proliferation-induced hepatic oxidative damage. Biochem Pharmacol, 53, 1369–74
   PubMed Web of Science ®Google Scholar
• Sonich-Mullin C, Fielder R, Wiltse J, et al. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul Toxicol Pharmacol, 34, 146–52
   PubMed Web of Science ®Google Scholar
• Staels B, Schoonjans K, Fruchart JC, Auwerx J. (1997). The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Biochimie, 79, 95–9
   PubMed Web of Science ®Google Scholar
• Stanko RT, Sekas G, Isaacson IA, et al. (1995). Pyruvate inhibits clofibrate-induced hepatic peroxisomal proliferation and free radical production in rats. Metabolism, 44, 166–71
   PubMed Web of Science ®Google Scholar
• Stauber AJ, Brown-Borg H, Liu J, et al. (2005). Constitutive expression of peroxisome proliferator-activated receptor alpha-regulated genes in dwarf mice. Mol Pharmacol, 67, 681–94
   PubMedGoogle Scholar
• Stauber AJ, Bull RJ. (1997). Differences in phenotype and cell replicative behavior of hepatic tumors induced by dichloroacetate (DCA) and trichloroacetate (TCA). Toxicol Appl Pharmacol, 144, 235–46
   PubMed Web of Science ®Google Scholar
• Stoner MA, Auerbach SS, Zamule SM, et al. (2007). Transactivation of a DR-1 PPRE by a human constitutive androstane receptor variant expressed from internal protein translation start sites. Nucleic Acids Res, 35, 2177–90
   PubMedGoogle Scholar
• Styles JA, Kelly M, Pritchard NR, Elcombe CR. (1988). A species comparison of acute hyperplasia induced by the peroxisome proliferator methylclofenapate: involvement of the binucleated hepatocyte. Carcinogenesis, 9, 1647–55
   PubMedGoogle Scholar
• Styles JA, Kelly MD, Pritchard NR, Elcombe CR. (1990). Acute hyperplasia and peroxisome proliferation induced by methylclofenapate: a species comparison and implications for liver carcinogenesis. Prog Clin Biol Res, 331, 385–93
   PubMedGoogle Scholar
• Surapureddi S, Viswakarma N, Yu S, et al. (2006). PRIC320, a transcription coactivator, isolated from peroxisome proliferator-binding protein complex. Biochem Biophys Res Commun, 343, 535–43
   PubMedGoogle Scholar
• Svoboda DJ, Azarnoff DL. (1979). Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res, 39, 3419–28
   PubMed Web of Science ®Google Scholar
• Tachibana K, Kobayashi Y, Tanaka T, et al. (2005). Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. Nucl Recept, 3, 1--17
   PubMedGoogle Scholar
• Tai ES, Demissie S, Cupples LA, et al. (2002). Association between the PPARΑ L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol, 22, 805–10
   PubMed Web of Science ®Google Scholar
• Takacs ML, Abbott BD. (2007). Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol Sci, 95, 108–17
   PubMed Web of Science ®Google Scholar
• Takagi AK, Sai T, Umemura R, et al. (1990). Significant increase of 8-hydroxydeoxyguanosine in liver DNA of rats following short-term exposure to the peroxisome proliferators di(2-ethylhexyl)phthalate and di(2-ethylhexyl)adipate. Jpn J Cancer Res, 81, 213–5
   PubMedGoogle Scholar
• Takashima K, Ito Y, Gonzalez FJ, Nakajima T. (2008). Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and PPAR alpha-null mice. J Occup Health, 50, 169–80
   PubMed Web of Science ®Google Scholar
• Tamura K, Ono A, Miyagishima T, et al. (2006). Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators. J Toxicol Sci, 31, 471–90
   PubMedGoogle Scholar
• Tanaka K, Smith PF, Stromberg PC, et al. (1992). Studies of early hepatocellular proliferation and peroxisomal proliferation in Sprague Dawley rats treated with tumorigenic doses of clofibrate. Toxicol Appl Pharmacol, 116, 71–7
   PubMedGoogle Scholar
• Tanaka N, Moriya K, Kiyosawa K, et al. (2008a). Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor alpha in transgenic mice: implications for HCV-associated hepatocarcinogenesis. Int J Cancer, 122, 124–31
   PubMed Web of Science ®Google Scholar
• Tanaka N, Moriya K, Kiyosawa K, et al. (2008b). PPARα activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest, 118, 683–94
   PubMed Web of Science ®Google Scholar
• Tharappel JC, Cunningham ML, Spear BT, Glauert HP. (2001). Differential activation of hepatic NF-kappaB in rats and hamsters by the peroxisome proliferators Wy-14 643, gemfibrozil, and dibutyl phthalate. Toxicol Sci, 62, 20–7
   PubMedGoogle Scholar
• Tharappel JC, Nalca A, Owens AB, et al. (2003). Cell proliferation and apoptosis are altered in mice deficient in the NF-kappaB p50 subunit after treatment with the peroxisome proliferator ciprofibrate. Toxicol Sci, 75, 300–8
   PubMedGoogle Scholar
• Thoolen B, Maronpot RR, Harada T, et al. (2010). Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. Toxicol Pathol, 38, 5S--81S
   Google Scholar
• Thottassery J, Winberg L, Youssef J, et al. (1992). Regulation of perfluorooctanoic acid-induced peroxisomal enzyme activities and hepatocellular growth by adrenal hormones. Hepatology, 15, 316–22
   PubMed Web of Science ®Google Scholar
• Tomaszewski KE, Heindel SW, Jenkins WL, Melnick RL. (1990). Induction of peroxisomal acyl CoA oxidase activity and lipid peroxidation in primary rat hepatocyte cultures. Toxicology, 65, 49–60
   PubMedGoogle Scholar
• Traub O, Drüge PM, Willecke K. (1983). Degradation and resynthesis of gap junction protein in plasma membranes of regenerating liver after partial hepatectomy or cholestasis. Proc Natl Acad Sci U S A, 80, 755--9
   Google Scholar
• Trosko JE, Chang CC, Madhukar BV. (1990). Modulation of intercellular communication during radiation and chemical carcinogenesis. Radiat Res, 123, 241–51
   PubMed Web of Science ®Google Scholar
• Tucker MJ, Orton TC. (1995). Comparative toxicology of hypolipidaemic fibrates. Bristol (PA): Taylor and Francis
   Google Scholar
• Tugwood JD, Aldridge TC, Lambe KG, et al. (1996). Peroxisome proliferator-activated receptors: structures and function. Ann N Y Acad Sci, 804, 252–65
   PubMed Web of Science ®Google Scholar
• Tugwood JD, Holden PR, James NH, et al. (1998). A PPAR alpha cDNA cloned from guinea pig liver encodes a protein with similar properties to the mouse PPAR alpha: implications for species differences in response to peroxisome proliferators. Arch Toxicol, 72, 169–77
   PubMed Web of Science ®Google Scholar
• U.S. Environmental Protection Agency. (2005). Guidelines for carcinogen risk assessment and supplemental guidance for assessing susceptibility from early-life exposure to carcinogens. Fed Reg, 70, 66, 17765–817
   Google Scholar
• Upham BL, Deocampo ND, Wurl B, Trosko JE. (1998). Inhibition of gap junctional intercellular communication by perfluorinated fatty acids is dependent on the chain length of the fluorinated tail. Int J Cancer, 78, 491–5
   PubMed Web of Science ®Google Scholar
• Valles EG, Laughter AR, Dunn CS, et al. (2003). Role of the peroxisome proliferator-activated receptor alpha in responses to diisononyl phthalate. Toxicology, 191, 211–25
   PubMed Web of Science ®Google Scholar
• Van Rafelghem MJ, Mattie DR, Bruner RH, Andersen ME. (1987). Pathological and hepatic ultrastructural effects of a single dose of perfluoro-n-decanoic acid in the rat, hamster, mouse, and guinea pig. Fundam Appl Toxicol, 9, 522–40
   PubMedGoogle Scholar
• Vanden Heuvel JP, Kreder D, Belda B, et al. (2003). Comprehensive analysis of gene expression in rat and human hepatoma cells exposed to the peroxisome proliferator WY14 643. Toxicol Appl Pharmacol, 188, 185–98
   PubMedGoogle Scholar
• Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ. (2006). Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci, 92, 476–89
   PubMed Web of Science ®Google Scholar
• Varanasi U, Chu R, Huang Q, et al. (1996). Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem, 271, 2147–55
   PubMedGoogle Scholar
• Vu-Dac N, Schoonjans K, Kosykh V, et al. (1995). Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest, 96, 741–50
   PubMed Web of Science ®Google Scholar
• Vu-Dac N, Schoonjans K, Laine B, et al. (1994). Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem, 269, 31012–8
   PubMed Web of Science ®Google Scholar
• Wada N, Marsman DS, Popp JA. (1992). Dose-related effects of the hepatocarcinogen, Wy-14 643, on peroxisomes and cell replication. Fundam Appl Toxicol, 18, 149–54
   PubMedGoogle Scholar
• Wahli W, Braissant O, Desvergne B. (1995). Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol, 2, 261–6
   PubMed Web of Science ®Google Scholar
• Ward JM, Hagiwara A, Anderson LM, et al. (1988). The chronic hepatic or renal toxicity of di(2-ethylhexyl) phthalate, acetaminophen, sodium barbital, and phenobarbital in male B6C3F1 mice: autoradiographic, immunohistochemical, and biochemical evidence for levels of DNA synthesis not associated with carcinogenesis or tumor promotion. Toxicol Appl Pharmacol, 96, 494–506
   PubMed Web of Science ®Google Scholar
• Watanabe T, Horie S, Yamada J, et al. (1989). Species differences in the effects of bezafibrate, a hypolipidemic agent, on hepatic peroxisome-associated enzymes. Biochem Pharmacol, 38, 367–71
   PubMed Web of Science ®Google Scholar
• Weglarz TC, Sandgren EP. (2004). Cell cross-talk mediates PPARα null hepatocyte proliferation after peroxisome proliferator exposure. Carcinogenesis, 25, 107–12
   PubMed Web of Science ®Google Scholar
• West D, James N, Holden P, et al. (1999). Role for tumour necrosis factor a (TNFa) receptor 1 (TNFR1) and interleukin 1 receptor (IL1R) in the suppression of apoptosis by peroxisome proliferators. Hepatology, 30, 1417–24
   PubMedGoogle Scholar
• Wheeler MD, Smutney OM, Check JF, et al. (2003). Impaired Ras membrane association and activation in PPARα knockout mice after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol, 284, G302–12
   Google Scholar
• Williams GM, Perrone C. (1995). Mechanism based risk assessment of peroxisome proliferating rodent hepatocarcinogens. In: Peroxisomes: Biology and Role in Toxicology and Disease, eds. J.K. Reddy, T. Suga, and G.P. Mannaerts. Ann NY Acad Sci, 804, 554–72
   Google Scholar
• Wolf DC, Moore T, Abbott BD, et al. (2008). Comparative hepatic effects of perfluorooctanoic acid and WY 14 643 in PPARα knockout and wild-type mice. Toxicol Pathol, 36, 632–9
   PubMed Web of Science ®Google Scholar
• Woods CG, Burns AM, Bradford BU, et al. (2007a). WY-14 643 induced cell proliferation and oxidative stress in mouse liver are independent of NADPH oxidase. Toxicol Sci, 98, 366–74
   PubMedGoogle Scholar
• Woods CG, Burns AM, Maki A, et al. (2007b). Sustained formation of alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone radical adducts in mouse liver by peroxisome proliferators is dependent upon peroxisome proliferator-activated receptor-alpha, but not NADPH oxidase. Free Radic Biol Med, 42, 335–42
   PubMedGoogle Scholar
• Woods CG, Kosyk O, Bradford BU, et al. (2007c). Time course investigation of PPARα- and Kupffer cell-dependent effects of WY-14 643 in mouse liver using microarray gene expression. Toxicol Appl Pharmacol, 225, 267–77
   PubMed Web of Science ®Google Scholar
• Woodyatt NJ, Lambe KG, Myers KA, et al. (1999). The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. Carcinogenesis, 20, 369–72
   PubMed Web of Science ®Google Scholar
• Xiao S, Anderson SP, Swanson C, et al. (2006). Activation of peroxisome proliferator-activated receptor alpha enhances apoptosis in the mouse liver. Toxicol Sci, 92, 368–77
   PubMed Web of Science ®Google Scholar
• Xu HE, Li Y. (2008). Ligand-Dependent and -Independent Regulation of PPAR{gamma} and Orphan Nuclear Receptors. Sci Signal, 1, pe52
   PubMedGoogle Scholar
• Yamakawa-Kobayashi K, Ishiguro H, Arinami T, et al. (2002). A Val227Ala polymorphism in the peroxisome proliferator activated receptor alpha (PPARα) gene is associated with variations in serum lipid levels. J Med Genet, 39, 189–91
   PubMedGoogle Scholar
• Yamasaki H. (1990). Gap-junctional intercellular communication and carcinogenesis. Carcinogenesis, 11, 1051–8
   PubMed Web of Science ®Google Scholar
• Yang Q, Ito S, Gonzalez FJ. (2007). Hepatocyte-restricted constitutive activation of PPAR alpha induces hepatoproliferation but not hepatocarcinogenesis. Carcinogenesis, 28, 1171–7
   PubMedGoogle Scholar
• Yang Q, Nagano T, Shah Y, et al. (2008). The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci, 101, 132–9
   PubMed Web of Science ®Google Scholar
• Yeldandi AV, Milano M, Subbarao V, et al. (1989). Evaluation of liver cell proliferation during ciprofibrate-induced hepatocarcinogenesis. Cancer Lett, 47, 21–7
   PubMedGoogle Scholar
• Yeldandi AV, Rao MS, Reddy JK. (2000). Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. Mutat Res, 448, 159–77
   PubMed Web of Science ®Google Scholar
• Youssef JA, Bouziane M, Badr MZ. (2003). Age-dependent effects of nongenotoxic hepatocarcinogens on liver apoptosis in vivo. Mech Ageing Dev, 124, 333–40
   PubMedGoogle Scholar